Recruiting
Small cell lung cancer
RecruitingA Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer
Registered drugNo placebo
A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer
Registered drugNo placebo
- Disease:Small cell lung cancer
- Substances:TopotecanHUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST SEZ6, CONJUGATED TO (2S)-2-(2-BROMOACETAMIDO)-N-[(2S)-1-({3-[(7S)-7-ETHYL-7-HYDROXY-8,11-DIOXO-7,8,11,13-TETRAHYDRO-2H,10H-[1,3]DIOXOLO[4,5-G]PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-14-YL]BICYCLO[1.1.1]PENTAN-1-YL}AMINO)-1-OXOPROPAN-2-YL]-3-METHYLBUTANAMIDE
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Topotecan
